Frankfurt
21.01.25
15:14 Uhr
0,135 Euro
+0,058
+75,32 %
+75,32 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | AlzeCure's NeuroRestore ACD856 to be presented at AD/PD 2025 | 1 | PharmaTimes | ||
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | AlzeCure Pharma: AlzeCure Receives Abstract Acceptance at Alzheimer's Congress AD/PD 2025 on NeuroRestore ACD856 | 187 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / January 21, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 27.11.24 | AlzeCure Pharma: AlzeCure to Present at the Pharma Outsourcing Conference in Stockholm | 221 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 27, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops small molecule drugs for... ► Artikel lesen | |
| 26.11.24 | AlzeCure Pharma to Present at Redeye Life Science Day on December 3 | 202 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 26, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 20.11.24 | AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm | 300 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / November 20, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 11.11.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - September 2024 | 657 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / November 11, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR) today announced that its interim report for the period January - September... ► Artikel lesen | |
| 30.10.24 | AlzeCure Pharma: AlzeCure Presents New Anti-Inflammatory Data with NeuroRestore ACD856 at the Alzheimer's Conference CTAD | 426 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 30, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 28.10.24 | AlzeCure Pharma: AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis | 231 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for CNS diseases... ► Artikel lesen | |
| 24.10.24 | AlzeCure Pharma: AlzeCure to Present at the International Partnering Conference Bioscience 2024 on November 7 | 282 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 24, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 17.10.24 | AlzeCure Pharma's CEO Martin Jönsson to present at Redeye's Neurology Day | 235 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 17, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 10.10.24 | AlzeCure Pharma Broadcasts Live Event About the Phase II Candidate ACD440 Against Neuropathic Pain | 252 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / October 10, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 02.10.24 | AlzeCure's abstract on ACD856's effects to be presented at Alzheimer's conference | 5 | PharmaTimes | ||
| 01.10.24 | AlzeCure Pharma: AlzeCure's Abstract on ACD856's Anti-inflammatory Effects to be Presented at a Leading Alzheimer's Conference | 269 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / October 1, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 26.08.24 | AlzeCure Pharma: AlzeCure Publishes its Interim Report for January - June 2024 | 454 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 26, 2024 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced that its interim report for the period January - June... ► Artikel lesen | |
| 13.08.24 | AlzeCure Pharma: New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer's Disease | 683 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 07.08.24 | AlzeCure Pharma: New Results from AlzeCure's Pain Project TrkA-NAM Presented at the Pain Conference IASP 2024 | 289 | ACCESS Newswire | STOCKHOLM, SE / ACCESSWIRE / August 07, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting... ► Artikel lesen | |
| 13.06.24 | AlzeCure Pharma: New Scientific Article Published on Positive Clinical Results with Painless ACD440 Against Neuropathic Pain | 373 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / June 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases... ► Artikel lesen | |
| 28.05.24 | Nasdaq Stockholm AB: New last day of trading in paid subscription shares (BTA) of AlzeCure Pharma AB (publ) | 231 | GlobeNewswire | At the request of AlzeCure Pharma AB (publ), the last trading day in AlzeCure
Pharma AB (publ)'s paid subscription units will be changed from May 30, 2024 to
May 31, 2024.
Short name: ALZCUR BTA... ► Artikel lesen | |
| 15.05.24 | AlzeCure Pharma: Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Elected as a New Board Member | 612 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / May 15, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer's... ► Artikel lesen | |
| 14.05.24 | Communiqué from the Annual General Meeting of AlzeCure Pharma on 14 May 2024 | 679 | ACCESS Newswire | STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) Today, 14 May 2024, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below is a... ► Artikel lesen |
Seite:
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 410,70 | -0,01 % | HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws' | ||
| VIATRIS | 10,845 | -0,14 % | Viatris-Aktie: Kurs heute im Minus (10,8872 €) | Das Wertpapier von Viatris notiert am Mittwoch ein wenig leichter. Der jüngste Kurs betrug 11,20 US-Dollar. Für die Aktie von Viatris steht gegenwärtig ein Minus von 4,44 Prozent zu Buche. Das Papier... ► Artikel lesen | |
| OPKO HEALTH | 1,371 | -3,21 % | Opko Health CEO Phillip Frost kauft Stammaktien im Wert von 220.425 US-Dollar | ||
| JAGUAR HEALTH | 0,838 | 0,00 % | Jaguar Health-Aktie erreicht 52-Wochen-Tief bei 0,84 US-Dollar | ||
| ALTIMMUNE | 6,622 | +0,96 % | Altimmune, Inc: Altimmune Added to Nasdaq Biotechnology Index | GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 1,114 | +2,20 % | SELLAS Life Sciences Group, Inc. - 8-K, Current Report | ||
| AURINIA PHARMACEUTICALS | 7,470 | +0,62 % | Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS Growth and AUR200 Development | ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the third quarter and nine months... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 3,980 | 0,00 % | KIORA PHARMACEUTICALS INC - 8-K, Current Report | ||
| PHOTOCURE | 4,350 | -3,23 % | Photocure ASA: Results for the third quarter of 2024 | OSLO, Norway, Nov. 13, 2024 /PRNewswire/ -- Photocure ASA (OSE: PHO) today reported Hexvix®/Cysview® revenues of NOK 120.1 million in the third quarter of 2024 (Q3 2023: NOK 107.3 million)... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 2,487 | +0,24 % | Aclaris Therapeutics, Inc.: Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WAYNE, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the "Company" or "Aclaris"), a clinical-stage biopharmaceutical company focused on developing novel drug candidates... ► Artikel lesen | |
| LIPOCINE | 4,680 | +6,36 % | Lipocine Inc.: FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis | SALT LAKE CITY, Dec. 17, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| EUROBIO SCIENTIFIC | 24,950 | +0,40 % | Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners | Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners Paris... ► Artikel lesen | |
| MEDICURE | 0,525 | 0,00 % | Medicure, Inc.: Medicure Reports Financial Results For Quarter Ended September 30, 2024 | WINNIPEG, MB / ACCESSWIRE / November 25, 2024 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals... ► Artikel lesen | |
| BAYER | 21,440 | +0,75 % | Bayer-Aktie mit Kursgewinnen (21,15 €) | Der Anteilsschein von Bayer notiert heute fester. Das Papier kostete zuletzt 21,15 Euro. Am Aktienmarkt liegt das Wertpapier von Bayer gegenwärtig im Plus. Die Aktie legte um 41 Cent zu. Der Anteilsschein... ► Artikel lesen | |
| MERCK KGAA | 144,30 | +1,62 % | Merck Aktie: Erfolgswelle schwappt weiter! | Die Merck-Aktie zeigte am heutigen Handelstag eine volatile Entwicklung an der XETRA-Börse. Der Anteilsschein bewegte sich in einer Spanne zwischen 141,50 und 144,55 Euro, wobei das Handelsvolumen sich... ► Artikel lesen |
Das Unternehmen ALZECURE PHARMA AB kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +75,32 % bei einem Aktienkurs von 0,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.
